Victory Capital Management Inc. Has $2.35 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Key Points

• Victory Capital Management Inc. increased its stake in Amphastar Pharmaceuticals by 27.9%, owning 81,087 shares valued at $2.35 million after acquiring an additional 17,700 shares in the first quarter.
• Several institutional investors, including Signaturefd LLC and GAMMA Investing LLC, have also raised their holdings in Amphastar Pharmaceuticals recently, indicating increased institutional interest in the company.
• Analysts have issued mixed ratings on AMPH, with JPMorgan reducing its price target to $30.00 while Wells Fargo set a target at $35.00, reflecting ongoing uncertainties in the stock's outlook.

Victory Capital Management Inc. increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 27.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,087 shares of the company's stock after buying an additional 17,700 shares during the quarter. Victory Capital Management Inc. owned 0.17% of Amphastar Pharmaceuticals worth $2,351,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMPH. Hohimer Wealth Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 6.9% in the 1st quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company's stock valued at $232,000 after buying an additional 520 shares during the period. Signaturefd LLC increased its stake in shares of Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after purchasing an additional 520 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Amphastar Pharmaceuticals by 15.7% in the 1st quarter. New York State Common Retirement Fund now owns 81,565 shares of the company's stock valued at $2,365,000 after purchasing an additional 11,075 shares in the last quarter. SteelPeak Wealth LLC purchased a new position in shares of Amphastar Pharmaceuticals in the 1st quarter valued at about $1,617,000. Finally, Significant Wealth Partners LLC increased its stake in shares of Amphastar Pharmaceuticals by 43.2% in the 1st quarter. Significant Wealth Partners LLC now owns 10,215 shares of the company's stock valued at $296,000 after purchasing an additional 3,080 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded down $0.12 during trading on Friday, hitting $20.84. 92,059 shares of the company's stock traded hands, compared to its average volume of 560,399. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96. The company has a market cap of $982.16 million, a PE ratio of 7.55 and a beta of 0.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02. The firm's fifty day moving average price is $23.84 and its 200 day moving average price is $27.00.

Analyst Ratings Changes

Several research analysts have recently weighed in on AMPH shares. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Finally, Wells Fargo & Company cut their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Hold" and an average target price of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.